Six-minute walking versus shuttle walking: responsiveness to bronchodilation in chronic obstructive pulmonary disease

Pepin, Véronique; Brodeur, Julie; Lacasse, Yves; Milot, Julie; LeBlanc, Pierre; Whittom, François; Maltais, François
April 2007
Thorax;Apr2007, Vol. 62 Issue 4, p291
Academic Journal
Background: The responsiveness of the endurance shuttle walk to functional changes following bronchodilation has recently been reported. The current literature suggests that the 6 min walking test (6MWr) is less responsive to bronchodilation than the endurance shuttle walk. Aim: To compare bronchodilator-induced changes in exercise performance with the 6MWT and the endurance shuttle walk. Methods: In a randomised, double-blind, placebo-controlled, crossover trial, 14 patients with chronic obstructive pulmonary disease (forced expiratory volume in 1 s (FEV1) 50 (8)% predicted) completed two 6MWTs and two endurance shuttle walks, each preceded by nebulised placebo or 500 pg ipratropium bromide. Cardiorespiratory parameters were monitored during each walking test with a portable telemetric gas analyser. Quadriceps twitch force was measured by magnetic stimulation of the femoral nerve before and after each walking test. Results: The 6 min walking distance did not change significantly after bronchodilation despite a significant increase in FEV1 of 0.18 (0.09) litres (p<0.001). A similar change in FEV1 (0.18 (0.12) litres, p<0.001 ) was associated with a significant improvement in the distance walked on the endurance shuttle walk (δdistance ipratropium bromide - placebo = 144 (219) m, p = 0.03). Quadriceps muscle fatigue was infrequent (<15% of patients) after both walking tests. Conclusion: The endurance shuttle walk is more responsive than the 6MWT for detecting changes in exercise performance following bronchodilation.


Related Articles

  • Combination therapy for exercise intolerance in COPD. R. Casaburi // Thorax;Jul2006, Vol. 61 Issue 7, p551 

    The article comments on the recent approaches that will improve the exercise intolerance of patients with chronic obstructive pulmonary disease (COPD) due to dynamic hyperinflation. The methods under consideration are oxygen supplementation, treatment with bronchodilators, combination of helium...

  • Exercise in COPD: damned IF you dc and damned if you don't. Macklem, P. T. // Thorax;Nov2005, Vol. 60 Issue 11, p887 

    The article focuses on the effect of bronchodilators in chronic obstructive pulmonary disease (COPD). In the article, it is found that the patient population separated cleanly into two groups: those whose exercise endurance was improved and those whose exercise endurance decreased. This...

  • Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study. Berton, Danilo Cortozi; dos Santos, Álvaro Huber; Bohn Jr., Ivo; de Lima, Rodrigo Quevedo; Breda, Vanderléia; Zimermann Teixeira, Paulo José // Jornal Brasileiro de Pneumologia;set/out2016, Vol. 42 Issue 5, p367 

    Objective: To compare a once-daily long-acting β2 agonist (indacaterol 150 μg) with a once-daily long-acting anticholinergic (tiotropium 5 μg) in terms of their effects on exercise endurance (limit of tolerance, Tlim) in patients with moderate COPD. Secondary endpoints were their...

  • Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD. Peters, M. M.; A.^ Webb, K.; O'Donnell, D. E. // Thorax;Jul2006, Vol. 61 Issue 7, p559 

    Background: Studies examining the physiological interactions of oxygen (O2) and bronchodilators (BD) during exercise in chronic obstructive pulmonary disease (COPD) should provide new insights into mechanisms of exercise intolerance. We examined the effects of O2 and BD, alone and in...

  • Assessing the exercise response to a bronchodilator in COPD: time to get off your bike? Morgan, M. D. I.; Singh, S. J. // Thorax;Apr2007, Vol. 62 Issue 4, p281 

    The author reflects on the medical tests used to asses the exercise response to a bronchodilator in chronic obstructive pulmonary disease (COPD). He said that when using exercise tests for therapeutic intervention in COPD, one must understand the nature of such test and its implications. He...

  • The Continuum of Physiological Impairment during Treadmill Walking in Patients with Mild-to-Moderate COPD: Patient Characterization Phase of a Randomized Clinical Trial. O’Donnell, Denis E.; Maltais, François; Porszasz, Janos; Webb, Katherine A.; Albers, Frank C.; Deng, Qiqi; Iqbal, Ahmar; Paden, Heather A.; Casaburi, Richard // PLoS ONE;May2014, Vol. 9 Issue 5, p1 

    Background: To have a better understanding of the mechanisms of exercise limitation in mild-to-moderate chronic obstructive pulmonary disease (COPD), we compared detailed respiratory physiology in patients with COPD and healthy age- and sex-matched controls. Methods: Data were collected during...

  • A review of bronchodilators for chronic obstructive pulmonary disease. Smith, Haley // South African Pharmaceutical Journal;2013, Vol. 80 Issue 7, p9 

    Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that is associated with airway obstruction. COPD is a major cause of chronic morbidity and mortality throughout the world. It is a progressive condition, but is partially reversible through treatment, especially when...

  • Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: A study level and a patient level network meta-analysis. Cope, Shannon; Jie Zhang; Williams, James; Jansen, Jeroen P. // BMC Pulmonary Medicine;2012, Vol. 12 Issue 1, p29 

    Background: The objective of this study was to evaluate the comparative efficacy of indacaterol 75 µg once daily (OD), tiotropium 18 µg OD, salmeterol 50 µg twice daily (BID), formoterol 12 µg BID, and placebo for the treatment of chronic obstructive pulmonary disease (COPD) based on...

  • Novartis's novel bronchodilator paves way for potent COPD combinations.  // PharmaWatch: Monthly Review;Jul2005, Vol. 4 Issue 7, p25 

    The article reports on the results of phase II clinical trial of indacaterol, a novel bronchodilator agent from Novartis AG. According to the company, indacaterol is a once-daily bronchodilator with a long duration of action, rapid onset of action and clean side effects profile. The drug, with...


Read the Article


Sign out of this library

Other Topics